Heritage products are now offered on the two largest medical platforms in Canada
TORONTO, June 06, 2022–(BUSINESS WIRE)–Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage of the “Company”), is pleased to announce that it has signed a definitive agreement for the supply of its products to a major LP with the #1 leading market share for sale on its medical platform.
The major LP has completed its initial purchase of Heritage brands, including RAD, Premium 5, and CB4, and are now offering Heritage products on the platform with the first shipment of 12 stock keeping units (“SKUs”) completed in May.
The relationship will also encompass white labelling of some products based on Heritage’s product quality, variety, consistency, industry proven technology and innovation.
“This LP is a leader in the online medical and recreational cannabis space, and we are very honoured that they are trusting Heritage to be a part of their medical platform,” said David Schwede, CEO of Heritage. “We have added yet another revenue channel to further support our growing business, and now that our products are on the two largest medical platforms in Canada, our positive trajectory and momentum are hitting pace. We are thankful for this opportunity to work with this team and are excited for what the future of the relationship can bring”.
About Heritage
Heritage Cannabis is a leading cannabis company offering innovative products to both the medical and recreational legal cannabis markets in Canada and the U.S., operating under two licensed manufacturing facilities in Canada. The company has an extensive portfolio of high-quality cannabis products under the brands Purefarma, Pura Vida, RAD, Premium 5, feelgood., CB4 suite of medical products in Canada, and ArthroCBD in the US.
ON BEHALF OF THE BOARD OF DIRECTORS OF HERITAGE CANNABIS HOLDINGS CORP.
“David Schwede”
David Schwede
CEO
The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005625/en/
Contacts
Kelly Castledine
Tel: 647-660-2560
